Mesoblast Limited (MSB.AX)
AUD 1.8
(-2.44%)
AUD 1.8
(-2.44%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 102.43 Million USD | -2.26% |
| 2023 | 106.48 Million USD | 7.88% |
| 2022 | 98.7 Million USD | 99.28% |
| 2021 | 49.53 Million USD | -21.8% |
| 2020 | 63.34 Million USD | -5.85% |
| 2019 | 67.27 Million USD | 13.27% |
| 2018 | 59.39 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 110.61 Million USD | 7.59% |
| 2024 FY | 102.43 Million USD | -3.8% |
| 2024 Q4 | 102.43 Million USD | 0.0% |
| 2024 Q2 | 110.61 Million USD | -3.06% |
| 2023 Q2 | 101.98 Million USD | 1.44% |
| 2023 Q4 | 106.48 Million USD | 2.69% |
| 2023 FY | 106.48 Million USD | 7.88% |
| 2023 Q3 | 103.68 Million USD | 1.67% |
| 2023 Q1 | 100.53 Million USD | 1.86% |
| 2022 Q2 | 94.48 Million USD | 88.18% |
| 2022 Q1 | 50.2 Million USD | 1.37% |
| 2022 Q3 | 96.69 Million USD | 2.34% |
| 2022 Q4 | 98.7 Million USD | 2.07% |
| 2022 FY | 98.7 Million USD | 99.28% |
| 2021 Q3 | 46.32 Million USD | -16.68% |
| 2021 FY | 49.53 Million USD | -21.8% |
| 2021 Q1 | 63.14 Million USD | -0.31% |
| 2021 Q2 | 55.59 Million USD | -11.95% |
| 2021 Q4 | 49.53 Million USD | 6.92% |
| 2020 Q1 | 68.79 Million USD | 2.26% |
| 2020 Q2 | 72.67 Million USD | 5.64% |
| 2020 Q3 | 65.71 Million USD | -9.58% |
| 2020 Q4 | 63.34 Million USD | -3.61% |
| 2020 FY | 63.34 Million USD | -5.85% |
| 2019 Q4 | 67.27 Million USD | -4.19% |
| 2019 Q3 | 70.21 Million USD | 16.28% |
| 2019 Q2 | 60.38 Million USD | -1.26% |
| 2019 Q1 | 61.15 Million USD | 2.97% |
| 2019 FY | 67.27 Million USD | 13.27% |
| 2018 Q4 | 59.39 Million USD | 89.03% |
| 2018 FY | 59.39 Million USD | 0.0% |
| 2018 Q3 | 31.42 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q3 | - USD | -100.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | 233 Thousand USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AdAlta Limited | 1.08 Million AUD | -9303.202% |
| Acrux Limited | - AUD | -Infinity% |
| Actinogen Medical Limited | - AUD | -Infinity% |
| AnteoTech Limited | 19.22 Thousand AUD | -532666.422% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 51.91 Thousand AUD | -197216.716% |
| Amplia Therapeutics Limited | 13.89 Thousand AUD | -737213.755% |
| Avecho Biotechnology Limited | 98.22 Thousand AUD | -104186.078% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Biome Australia Limited | - AUD | -Infinity% |
| Biotron Limited | - AUD | -Infinity% |
| Botanix Pharmaceuticals Limited | - AUD | -Infinity% |
| BTC Health Limited | - AUD | -Infinity% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| CSL Limited | 14.48 Billion AUD | 99.293% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 509.92 Thousand AUD | -19988.327% |
| Cynata Therapeutics Limited | - AUD | -Infinity% |
| Dimerix Limited | 69.51 Thousand AUD | -147254.566% |
| EZZ Life Science Holdings Limited | - AUD | -Infinity% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | - AUD | -Infinity% |
| Immuron Limited | 132.94 Thousand AUD | -76952.978% |
| Immutep Limited | 1.04 Million AUD | -9720.596% |
| Imugene Limited | - AUD | -Infinity% |
| Invex Therapeutics Ltd | - AUD | -Infinity% |
| Memphasys Limited | - AUD | -Infinity% |
| Nanollose Limited | - AUD | -Infinity% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| Noxopharm Limited | - AUD | -Infinity% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Nyrada Inc. | - AUD | -Infinity% |
| Orthocell Limited | 540.72 Thousand AUD | -18844.01% |
| PharmAust Limited | - AUD | -Infinity% |
| Patrys Limited | - AUD | -Infinity% |
| Paradigm Biopharmaceuticals Limited | 117.48 Thousand AUD | -87087.628% |
| Proteomics International Laboratories Limited | 221.03 Thousand AUD | -46242.92% |
| Prescient Therapeutics Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | - AUD | -Infinity% |
| Race Oncology Limited | - AUD | -Infinity% |
| Radiopharm Theranostics Limited | - AUD | -Infinity% |
| Recce Pharmaceuticals Ltd | 587.1 Thousand AUD | -17347.475% |
| Starpharma Holdings Limited | 1.95 Million AUD | -5134.287% |
| Telix Pharmaceuticals Limited | 15.88 Million AUD | -544.813% |
| Tissue Repair Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 2.11 Million AUD | -4746.638% |